ResMed

ResMed **Air** Solutions

Clear insight

As your partner supporting better patient care, ResMed gives you the clinical tools to gain greater insight into your sleep apnoea patients' therapy, so you can quickly and accurately provide treatment that's right for them.

The benefit of clear insight

Patients on fixed or auto-adjusting pressure devices sometimes exhibit breathing patterns associated with central sleep apnoea (CSA) or Cheyne–Stokes respiration (CSR). To help you identify and provide tailored care to these patients, ResMed's AirSense™ 10 sleep therapy devices feature CSA and CSR detection*, while ResMed's AirCurve™ 10 CS PaceWave™ device is specifically designed to treat CSA, mixed sleep apnoea and complex sleep apnoea (CompSA), as well as periodic breathing with or without obstructive sleep apnoea (OSA).

CSA detection

A central apnoea occurs when a patient stops breathing while their airway is open and not obstructed.

Once an apnoea has been detected, the CSA detection algorithm applies a forced oscillation technique (FOT) to determine if a patient's airway is open or closed during an apnoea. Using the FOT, small oscillations in pressure are added to the patient's therapy pressure to gauge the airflow response.

If no airflow is detected, the airway is deemed closed and the patient is most likely having an obstructive apnoea. In response, the device will intelligently increase therapy pressure according to the severity and duration of the apnoea.

If, however, airflow is detected after the FOT, the airway is deemed open and the patient is most likely having a central apnoea. In this case, the device will not increase therapy pressure.

It will instead record the central apnoea in the patient's apnoea–hypopnoea index, which you can monitor via AirView™ – ResMed's cloud-based patient management system.



Detecting CSA

CSR detection

Throughout the night, the intelligent CSR detection algorithm will continually monitor a patient's breathing pattern, checking for indications of CSR.

If these indications occur for a minimum of 15 minutes, the patient may be exhibiting CSR. These events are captured in your reports in AirView.

You will then be able to see how long the patient exhibited indications of CSR and for what percentage of their total nightly sleep.



Detecting indications of CSR

* CSA and CSR detection are available in the AirSense 10 Elite, AirSense 10 AutoSet™ and AirSense 10 AutoSet for Her devices.

Note: ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2–4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.

MANUFACTURER
ResMed Ltd
1 Elizabeth Macarthur Drive
Bella Vista NSW 2153 Australia